Free Trial

United Therapeutics (UTHR) Competitors

United Therapeutics logo
$438.75 +4.69 (+1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$438.89 +0.14 (+0.03%)
As of 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UTHR vs. ALNY, REGN, BIIB, INCY, NBIX, EXEL, BMRN, EXAS, IONS, and MDGL

Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.

United Therapeutics vs. Its Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 1.2% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

United Therapeutics has a net margin of 40.36% compared to Alnylam Pharmaceuticals' net margin of -12.96%. United Therapeutics' return on equity of 18.73% beat Alnylam Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals-12.96% -273.52% -7.39%
United Therapeutics 40.36%18.73%16.49%

Alnylam Pharmaceuticals presently has a consensus price target of $439.58, indicating a potential downside of 4.10%. United Therapeutics has a consensus price target of $438.85, indicating a potential upside of 0.02%. Given United Therapeutics' higher possible upside, analysts clearly believe United Therapeutics is more favorable than Alnylam Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
24 Buy rating(s)
0 Strong Buy rating(s)
2.86
United Therapeutics
0 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.69

Alnylam Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

In the previous week, United Therapeutics had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for United Therapeutics and 26 mentions for Alnylam Pharmaceuticals. United Therapeutics' average media sentiment score of 0.79 beat Alnylam Pharmaceuticals' score of 0.70 indicating that United Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
10 Very Positive mention(s)
2 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
United Therapeutics
18 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$2.25B26.72-$278.16M-$2.47-185.57
United Therapeutics$3.08B6.43$1.20B$25.6217.13

Summary

United Therapeutics beats Alnylam Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

Get United Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UTHR vs. The Competition

MetricUnited TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.79B$2.82B$5.74B$10.35B
Dividend YieldN/A53.63%5.53%4.58%
P/E Ratio17.1323.5276.3526.43
Price / Sales6.43510.85466.9890.96
Price / Cash14.61171.0137.4661.85
Price / Book3.045.2913.186.39
Net Income$1.20B$32.95M$3.29B$271.22M
7 Day Performance8.69%3.80%2.50%2.79%
1 Month Performance40.52%5.68%4.60%7.35%
1 Year Performance22.60%1.58%73.81%29.74%

United Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UTHR
United Therapeutics
4.5061 of 5 stars
$438.75
+1.1%
$438.85
+0.0%
+22.1%$19.79B$3.08B17.131,305Insider Trade
ALNY
Alnylam Pharmaceuticals
3.7531 of 5 stars
$461.14
-1.0%
$421.28
-8.6%
+67.2%$61.07B$2.46B-186.702,230
REGN
Regeneron Pharmaceuticals
4.7458 of 5 stars
$572.59
+2.2%
$817.67
+42.8%
-48.0%$60.69B$14.21B14.4315,106Positive News
BIIB
Biogen
4.6489 of 5 stars
$143.32
-1.1%
$181.65
+26.7%
-28.9%$21.01B$10.00B13.707,605Trending News
Analyst Forecast
INCY
Incyte
4.7557 of 5 stars
$83.14
+0.0%
$82.53
-0.7%
+31.8%$16.24B$4.24B18.902,617Analyst Forecast
NBIX
Neurocrine Biosciences
4.4537 of 5 stars
$140.44
-1.0%
$160.00
+13.9%
+24.3%$13.93B$2.51B41.551,800Positive News
Analyst Forecast
EXEL
Exelixis
4.7305 of 5 stars
$39.01
-0.4%
$44.06
+12.9%
+51.0%$10.50B$2.17B18.751,147Positive News
BMRN
BioMarin Pharmaceutical
4.9593 of 5 stars
$53.14
-1.8%
$92.04
+73.2%
-22.7%$10.20B$2.85B15.773,040Positive News
EXAS
Exact Sciences
4.7868 of 5 stars
$53.43
-0.9%
$68.05
+27.4%
-24.7%$10.12B$2.94B-9.847,000
IONS
Ionis Pharmaceuticals
3.9091 of 5 stars
$61.10
-3.3%
$67.88
+11.1%
+49.6%$9.74B$944.05M-33.211,069Trending News
Analyst Forecast
MDGL
Madrigal Pharmaceuticals
4.0604 of 5 stars
$425.60
-1.5%
$483.38
+13.6%
+96.4%$9.60B$515.55M-33.1290

Related Companies and Tools


This page (NASDAQ:UTHR) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners